These results suggest the potential protective effects of SGLT2 inhibitors against HCC development in high-risk patients, reinforcing the importance of targeted therapeutic strategies for managing HCC risk in patients with diabetes and chronic viral hepatitis. This evidence concerns the gene SLC5A2 and animal viral hepatitis.